Por: CNBC Health November 02, 2022
Pfizer CEO Albert Bourla talks during a press conference with European Commission President after a visit to oversee the production of the Pfizer-BioNtech Covid-19 vaccine at the factory of US pharmaceutical company Pfizer, in Puurs, on April 23, 2021.John Thys AFP Getty Images CEO Albert Bourla laid out his plan Tuesday to keep the pharmaceutical giant growing through 2030, as the Covid-19 pandemic fades and the company faces generic... + full article
Associated Press USA Health November 02, 2022
Pfizer’s COVID-19 treatment helped the pharmaceutical giant balance tumbling international sales for its coronavirus vaccine and top third-quarter expectations.The pill treatment Paxlovid brought in $7.5 billion in sales in the quarter and has generated more than $17 billion... + más
Covid-19 treatment Paxlovid can interact with common heart medications, doctors warn | CNN
Pfizer rides Paxlovid sales to better-than-expected quarter | ABC News
MarketWatch USA Business November 01, 2022
Pfizer’s CFO David Denton cited strong performance from the company’s Paxlovid and Eliquis products, particularly in the U.S., as well as the “continued impressive launch” of the Prevnar 20 vaccine for adults in the U.S. Paxlovid is an antiviral used to treat COVID-19,... + más
Pfizer climbs on strong Q3 results, raised outlook | MarketWatch
Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics | CNBC
ABC News USA Business November 01, 2022
Pfizer’s COVID-19 treatment helped the pharmaceutical giant balance tumbling international sales for its vaccine and top third-quarter expectations.The pill treatment Paxlovid brought in $7.5 billion in sales in the quarter and has generated more than $17 billion so far this... + más
Pfizer raises 2022 earnings guidance, beats third-quarter expectations | CNBC
CNBC USA Health November 01, 2022
In this articleVials containing the Pfizer/BioNtech vaccine against the coronavirus disease (COVID-19) are displayed before being used at a mobile vaccine clinic, in Valparaiso, Chile, January 3, 2022.Rodrigo Garrido Reuters on Tuesday raised its 2022 earnings guidance after... + más
Fox Business USA Business October 22, 2022
Fox News contributor Dr. Janette Nesheiwat discusses Pfizer’s new anti-viral COVID-19 pill and the importance of early treatment. has revealed the price it is eyeing in the U.S. for its adult COVID-19 vaccine on the commercial market. Ticker Security Last Change Change %... + más
Moderna sues Pfizer over patents behind COVID-19 vaccine | The Advocate
Pfizer says COVID-19 vaccine will cost $110-$130 per dose | ABC News
The Advocate USA Crime October 10, 2022
vaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main competitors of copying Moderna’s technology in order to make their own vaccine.Moderna said Friday that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed... + más
Moderna is suing Pfizer over its coronavirus vaccine | The Verge
Moderna vs Pfizer: Is it OK to mix and match the updated COVID-19 booster shots? | Los Angeles Times
About iurex | Privacy Policy | Disclaimer |